

Andrea R Beccari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/875717/publications.pdf>

Version: 2024-02-01

23
papers

1,061
citations

623188

14
h-index

610482

24
g-index

29
all docs

29
docs citations

29
times ranked

1871
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2716-2746.	2.9	149
2	Natural Compounds Inhibit SARS-CoV-2 nsp13 Unwinding and ATPase Enzyme Activities. <i>ACS Pharmacology and Translational Science</i> , 2022, 5, 226-239.	2.5	43
3	PKD-dependent PARP12-catalyzed mono-ADP-ribosylation of Golgin-97 is required for E-cadherin transport from Golgi to plasma membrane. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	16
4	Characterization of raloxifene as a potential pharmacological agent against SARS-CoV-2 and its variants. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	9
5	Cytopathic SARS-CoV-2 screening on VERO-E6 cells in a large-scale repurposing effort. <i>Scientific Data</i> , 2022, 9, .	2.4	17
6	Extensive Sampling of Molecular Dynamics Simulations to Identify Reliable Protein Structures for Optimized Virtual Screening Studies: The Case of the hTRPM8 Channel. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7558.	1.8	1
7	Combining Different Docking Engines and Consensus Strategies to Design and Validate Optimized Virtual Screening Protocols for the SARS-CoV-2 3CL Protease. <i>Molecules</i> , 2021, 26, 797.	1.7	14
8	A Blueprint for High Affinity SARS-CoV-2 Mpro Inhibitors from Activity-Based Compound Library Screening Guided by Analysis of Protein Dynamics. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1079-1095.	2.5	44
9	Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1096-1110.	2.5	101
10	X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease. <i>Science</i> , 2021, 372, 642-646.	6.0	240
11	Altered Local Interactions and Long-Range Communications in UK Variant (B.1.1.7) Spike Glycoprotein. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5464.	1.8	9
12	“Molecular Anatomy”: a new multi-dimensional hierarchical scaffold analysis tool. <i>Journal of Cheminformatics</i> , 2021, 13, 54.	2.8	12
13	Computational Studies of SARS-CoV-2 3CLpro: Insights from MD Simulations. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5346.	1.8	48
14	A Comprehensive Mapping of the Druggable Cavities within the SARS-CoV-2 Therapeutically Relevant Proteins by Combining Pocket and Docking Searches as Implemented in Pockets 2.0. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5152.	1.8	34
15	SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5707.	1.8	58
16	Binding Mode Exploration of B1 Receptor Antagonists™ by the Use of Molecular Dynamics and Docking Simulation—How Different Target Engagement Can Determine Different Biological Effects. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7677.	1.8	2
17	Combining Molecular Dynamics and Docking Simulations to Develop Targeted Protocols for Performing Optimized Virtual Screening Campaigns on the hTRPM8 Channel. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2265.	1.8	15
18	ADPredict: ADP-ribosylation site prediction based on physicochemical and structural descriptors. <i>Bioinformatics</i> , 2018, 34, 2566-2574.	1.8	17

#	ARTICLE	IF	CITATIONS
19	PARP1-produced poly-ADP-ribose causes the PARP12 translocation to stress granules and impairment of Golgi complex functions. <i>Scientific Reports</i> , 2017, 7, 14035.	1.6	76
20	Novel selective, potent naphthyl TRPM8 antagonists identified through a combined ligand- and structure-based virtual screening approach. <i>Scientific Reports</i> , 2017, 7, 10999.	1.6	23
21	Targeting the minor pocket of C5aR for the rational design of an oral allosteric inhibitor for inflammatory and neuropathic pain relief. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 16937-16942.	3.3	56
22	Use of Experimental Design To Optimize Docking Performance: The Case of LiGenDock, the Docking Module of Ligen, a New De Novo Design Program. <i>Journal of Chemical Information and Modeling</i> , 2013, 53, 1503-1517.	2.5	28
23	LiGen: A High Performance Workflow for Chemistry Driven de Novo Design. <i>Journal of Chemical Information and Modeling</i> , 2013, 53, 1518-1527.	2.5	45